INSM Stock Summary and Trading Ideas (Insmed | NASDAQ:INSM)

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Insmed trades on the NASDAQ stock market under the symbol INSM.

As of April 23, 2024, INSM stock price climbed to $25.27 with 1,962,472 million shares trading.

INSM has a beta of 0.91, meaning it tends to be less sensitive to market movements. INSM has a correlation of 0.10 to the broad based SPY ETF.

INSM has a market cap of $3.75 billion. This is considered a Mid Cap stock.

Last quarter Insmed reported $84 million in Revenue and -$1.28 earnings per share. This beat revenue expectation by $933,000 and missed earnings estimates by -$.13.

In the last 3 years, INSM stock traded as high as $36.97 and as low as $16.04.

The top ETF exchange traded funds that INSM belongs to (by Net Assets): VTI, VB, IWM, XBI, VXF.

INSM has outperformed the market in the last year with a return of +38.7%, while the SPY ETF gained +24.3%. However, in the most recent history, INSM shares have underperformed the stock market with its stock returning -11.4% in the last 3 month period and -10.1% for the last 2 week period, while SPY has returned +4.9% and -2.5%, respectively.

INSM support price is $23.44 and resistance is $24.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INSM stock will trade within this expected range on the day.